| Gemeten eigenschap | | Ver | Van | Tot | |
| translocaties acute leukemie bij diagnose, 5598 | | 1 | 11/22/2007 | 11/22/2010 | |
| translocatie acute leukemie bij follow-up, 5600 | | 1 | 11/22/2007 | 11/22/2010 | |
| t(2;5) NPM-ALK, 5504 | | 1 | 11/22/2007 | 11/22/2010 | |
| JAK2 exon 12 mutatie en MPL W515K/L genotypering, JAK2 exon 12 mutatie = 9341; MPL W515K/L genotypering = 9342 | | 1 | 03/21/2013 | 03/21/2016 | |
| Immuunglobuline (Ig) genherschikking bij verdachte lymfoproliferaties, 5730 (chronische diagnose); 5731 (chronische follow-up); 5732 (acute diagnose); 5733 (acute follow-up) | | 4 | 04/12/2013 | 04/12/2016 | |
| TCR genherschikking bij verdachte lymfoproliferaties, 5734 (chronisch diagnose); 5735 (chronisch follow-up); 5736 (acute diagnose); 5737 (acute follow-up) | | 4 | 04/12/2013 | 04/12/2016 | |
| IgH VH mutatie, 5520 | | 4 | 05/07/2014 | 05/07/2017 | |
| t(11;14) BCL1-IGH bij verdachte lymfoproliferaties, 5738 (diagnose) en 5739 (follow-up) | | 4 | 05/07/2014 | 05/07/2017 | |
| t(14;18) BCL2-IGH bij verdachte lymfoproliferaties, 5740 (diagnose) en 5741 (follow-up) | | 4 | 05/07/2014 | 05/07/2017 | |
| Factor II mutatie in bloed, 5521 | | 6 | 07/17/2014 | 07/17/2017 | |
| Factor V Leiden mutatie in bloed, 5522 | | 6 | 07/17/2014 | 07/17/2017 | |
| JAK2 V617F mutatie, 5528 | | 4 | 12/29/2014 | 12/29/2017 | |
| WT1 overexpressie, 5748 (BM, diagnose), 5749 (PB, diagnose), 5750 (BM, follow-up), 5751 (PB, follow-up) | | 5 | 01/15/2015 | 01/15/2018 | |
| t(9;22) BCR-ABL1 bij ALL, diagnose = 5747; follow-up = 5744 | | 5 | 02/02/2015 | 02/02/2018 | |
| t(9;22) BCR-ABL1 bij CML, diagnostische stalen = 5742, follow-up stalen = 5743 | | 5 | 02/02/2015 | 02/02/2018 | |
| Mutatie analyse bij AML d.m.v. NGS, 5764 | | 1 | 04/11/2016 | 04/11/2019 | |
| HLA-B*27 screening in bloed, 130 | | 6 | 10/06/2016 | 10/06/2019 | |
| Screening fusietranscripten bij acute leukemie (HemaVison-28Q RT-PCR), AML = 5791; ALL = 5792 | | 2 | 09/12/2018 | 09/12/2021 | |
| Opsporen van indel varianten in de genen CEBPA, FLT3 en NPM1 bij AML met behulp van fragmentanalyse, 5793 | | 3 | 11/14/2018 | 11/14/2021 | |
| Myc translocaties 5538, 5538 | | 1 | 03/04/2019 | 03/04/2022 | |
| pH in urine (POCT) | | 1 | 03/22/2019 | 03/22/2022 | |
| FISH BCL1-IGH t(11;14), 5534 | | 6 | 09/02/2019 | 09/02/2022 | |
| FISH BCL2-IGH t(14;18), 5535 | | 5 | 09/02/2019 | 09/02/2022 | |
| FISH CLL, 5533 of 5536 (enkel deletie 17p (p53)) | | 5 | 09/02/2019 | 09/02/2022 | |
| Chimerisme bepaling, 5514 (perifeer bloed), 5515 (beenmerg) | | 4 | 03/04/2020 | 03/04/2023 | |
| absoluut aantal lymfocyten in bloed, behoort tot profiel 120 (formule WBC) | | 6 | 03/17/2020 | 03/17/2023 | |
| Genetisch onderzoek naar dementie, 8525 (Dementie - Alzheimer dementie - Familiale Alzheimer dementie) | | 3 | 08/27/2020 | 08/27/2023 | |
| TPMT-genotypering in bloed, 9434 | | 4 | 11/20/2020 | 11/20/2023 | |
| Ziekte van Fabry | | 3 | 11/20/2020 | 11/20/2023 | |
| MRD in childhood ALL in beenmerg, 9275 (beenmerg) | | 1 | 11/20/2020 | 11/20/2023 | |